Chemotherapy · 2000 · 15 citations · 6 references
MedicineOncologyPharmacologyCancer PharmacologyCell SignalingNeoplasiaHormonal Cancer TherapyHormonal TherapyLung Cancer PharmacotherapyOncology PharmacologyPharmacodynamics Of Anticancer AgentsTumor PromotionCancer Cell Proliferation InhibitionEstrogen Receptor ExpressionEstrogen Receptor StatusEstrogen ReceptorsHormone Receptor ModulationTherapy-induced Growth InhibitionTumor Growth DynamicsTumor Growth Rate
We studied the antitumor activity of Navelbine (NVB) together with its ability to induce cellular differentiation and to influence estrogen receptor status of Lewis lung carcinoma (LLC). A total of 32 C(57)B1 mice divided into 5 groups were used for transplantation of LLC. Four groups of mice were treated with 5.0, 2.5 and 1.25 mg/kg/day from day 1 to 9 and 1.25 mg/kg on days 1, 7 and 13. Eight mice were controls. The dose of 1.25 mg/kg/day was the most effective and produced 72.7% inhibition of tumor growth. Ultrastructurally, on day 1 the cells showed poor differentiation. On day 14, in the case of 72.7% inhibition of tumor growth the study revealed a significant restoration of the morphology of the cells. Estrogen receptors gave a positive value in contrast to the initial measurement which was negative. The present study demonstrated good antitumor activity of NVB on LLC. NVB may also induce cellular differentiation and influence the estrogen receptor status.
6
Experimental antitumor activity of Navelbine.
S. CROS, Matthew C. Wright, M. Morimoto et al. · PubMed · 1989 · 128 citations
Medicine, Oncology, Pharmacology +6
Biochemical effects of Navelbine on tubulin and associated proteins.
PubMed · 1989 · 85 citations
Medicine, Oncology, Pharmacology +9